Biorestorative Therapies (BRTX) Stock News

BioRestorative (NASDAQ:BRTX) announced on October 22, 2025 the appointment of Crystal Romano as Head of Global Commercial Operations to lead global commercial operations and innovation for its cell-based product portfolio.

Ms. Romano brings 19 years of leadership in medical aesthetics and regenerative industries and has held roles at Cartessa, Lumenis, Integra LifeSciences, and MiMedx. At Cartessa she helped commercialize 11 new products and a biologics line in less than two years. The company said the hire aims to accelerate commercialization and unlock near-term revenue opportunities across its cell-based platforms.

BioRestorative Therapies (NASDAQ:BRTX) will participate in the 2025 Maxim Growth Summit in New York on October 22–23, 2025. CEO Lance Alstodt and VP of R&D Francisco Silva will join a panel titled “Stem Cell Therapy – A Space That is Ready to have its Day,” moderated by Jason McCarthy, Ph.D., Maxim Group. Management will also hold one-on-one meetings with institutional investors during the event. Due to the event format, no webcast will be available.

BioRestorative Therapies (NASDAQ:BRTX) announced that CEO Lance Alstodt was interviewed on "The Big Biz Show" on October 7, 2025. The interview covered BioRestorative’s recent clinical and regulatory milestones and highlighted commercial opportunities the company is pursuing.

The interview is being or will be broadcast on cable TV and streaming platforms including Roku, and on radio via The Biz Talk Radio Network, Armed Forces Radio, and iHeart Media across 175 countries. Podcasts are available on iHeart Radio, Apple Podcasts, Speaker.com, and TuneIn, and to subscribers of biztv.com and ytaclub.com.

BioRestorative Therapies (NASDAQ: BRTX) entered definitive agreements to sell 678,125 common shares at $1.60 per share in a registered direct offering, compared with a close of $1.50 on Oct 3, 2025. In a concurrent private placement, the company will issue unregistered warrants covering 508,594 shares (75% warrant coverage) with a $2.75 exercise price, exercisable six months after issuance through five years. Gross proceeds are $1.085 million before fees. Closing expected on or about Oct 8, 2025. Net proceeds will fund BRTX-100 clinical trials, ThermoStem preclinical R&D, biocosmeceuticals development, and general corporate purposes.

BioRestorative Therapies (NASDAQ:BRTX) reported its Q2 2025 financial results and business updates. The company achieved revenues of $303,000, marking a 240% increase from Q2 2024, primarily from BioCosmeceutical sales. The quarter ended with a net loss of $2.7 million ($0.30 per share), improved from a $4.0 million loss in Q2 2024.

Key developments include promising preliminary data from the BRTX-100 Phase 2 clinical trial for chronic lumbar disc disease, showing >50% improvement in both ODI and VAS metrics. The company maintains a strong financial position with $7.4 million in cash and investments with no debt. Additionally, BRTX announced a $2 million stock repurchase program through June 2026.

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET to discuss the results and provide business updates. Investors can join via domestic (1-888-506-0062) or international (1-973-528-0011) lines using access code 436077. The call will be available for replay on the company's website.

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced that CEO Lance Alstodt will be interviewed on the Benzinga All-Access Show on June 18, 2025, at 10:50 a.m. Eastern time. During the interview, the company plans to discuss BRTX-100 clinical data, leadership changes, and strategic updates. The interview will be accessible via live webcast and will later be archived on the company's website in the Investors section.

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company, has announced a $2 million share repurchase program effective through June 16, 2026. The company's Board of Directors authorized the buyback program, allowing management to repurchase shares through open market transactions or private negotiations. CEO Lance Alstodt expressed confidence in the company's clinical development pipeline and stated that the current share price does not reflect BioRestorative's intrinsic value. The timing, volume, and value of repurchases will be determined by management based on market conditions and other factors, with flexibility to modify or terminate the program at their discretion.

BioRestorative Therapies (NASDAQ: BRTX) presented promising preliminary data from its Phase 2 clinical trial of BRTX-100, an FDA fast-tracked autologous stem cell therapy for chronic lumbar disc disease (cLDD). The data, presented at ISSCR 2025, showed over 74% of subjects achieved >50% improvement in function and 72% reported >50% pain reduction by week 52. The trial has expanded from 15 to 36 subjects, progressing toward full enrollment of 99 participants. The therapy demonstrated an excellent safety profile with no serious adverse events reported between 26-104 weeks at the target dose. The FDA requires >30% improvement in function (ODI) and pain reduction (VAS) for trial continuation and BLA approval. The results consistently exceeded these thresholds, showing strengthening efficacy markers with each new data analysis.